Current Report Filing (8-k)
03 Août 2022 - 10:47PM
Edgar (US Regulatory)
0000894158 false 0000894158 2022-07-29
2022-07-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 29, 2022
SYNTHETIC BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
|
Nevada |
|
001-12584 |
|
13-3808303 |
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File No.) |
|
(IRS Employer Identification
No.)
|
9605 Medical Center Drive,
Suite 270
Rockville,
Maryland
20850
(Address of principal executive offices and zip code)
(301)
417-4364
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
| |
¨ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
| |
¨ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each
class |
Trading Symbol(s) |
Name of each exchange on which
registered |
|
Common stock, par value $0.001 per share |
SYN |
NYSE American LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in in Rule 405 of the Securities Act of 1933 (17
CFR §230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by checkmark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 3.03. Material Modification to rights of
Security Holders.
On July 29, 2022, the exercise price of warrants issued by
Synthetic Biologics, Inc. (the “Company”) in October 2018 (the
“Warrants”) was reduced from $6.90 per Warrant per full share of
the Company’s common stock, $0.001 par value per share (the “Common
Stock”), to $1.22 per Warrant per full share of Common Stock. The
reduction was the result of the issuance of shares of Preferred
Stock by the Company in a private placement.
Item 9.01. Financial Statements and Exhibits.
Exhibit
Number |
|
Description |
|
|
|
|
|
104 |
|
Cover
Page Interactive Data File (embedded within the XBRL
document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Dated:
August 3, 2022 |
SYNTHETIC
BIOLOGICS, INC. |
| |
|
|
|
| |
By: |
/s/
Steven A. Shallcross |
| |
|
Name: |
Steven
A. Shallcross |
| |
|
Title: |
Chief Executive Officer and Chief Financial Officer
|
Synthetic Biologics (AMEX:SYN)
Graphique Historique de l'Action
De Mar 2023 à Mar 2023
Synthetic Biologics (AMEX:SYN)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023
